Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis

The Lancet ◽  
2014 ◽  
Vol 384 (9944) ◽  
pp. 703-713 ◽  
Author(s):  
Laura J Sherrard ◽  
Michael M Tunney ◽  
J Stuart Elborn
2020 ◽  
Vol 19 (3) ◽  
pp. 370-375 ◽  
Author(s):  
Edith Zemanick ◽  
Pierre–Régis Burgel ◽  
Giovanni Taccetti ◽  
Alison Holmes ◽  
Felix Ratjen ◽  
...  

Antibiotics ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 766
Author(s):  
David F. Woods ◽  
Stephanie Flynn ◽  
Jose A. Caparrós-Martín ◽  
Stephen M. Stick ◽  
F. Jerry Reen ◽  
...  

The study of the respiratory microbiota has revealed that the lungs of healthy and diseased individuals harbour distinct microbial communities. Imbalances in these communities can contribute to the pathogenesis of lung disease. How these imbalances occur and establish is largely unknown. This review is focused on the genetically inherited condition of Cystic Fibrosis (CF). Understanding the microbial and host-related factors that govern the establishment of chronic CF lung inflammation and pathogen colonisation is essential. Specifically, dissecting the interplay in the inflammation–pathogen–host axis. Bile acids are important host derived and microbially modified signal molecules that have been detected in CF lungs. These bile acids are associated with inflammation and restructuring of the lung microbiota linked to chronicity. This community remodelling involves a switch in the lung microbiota from a high biodiversity/low pathogen state to a low biodiversity/pathogen-dominated state. Bile acids are particularly associated with the dominance of Proteobacterial pathogens. The ability of bile acids to impact directly on both the lung microbiota and the host response offers a unifying principle underpinning the pathogenesis of CF. The modulating role of bile acids in lung microbiota dysbiosis and inflammation could offer new potential targets for designing innovative therapeutic approaches for respiratory disease.


2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Claudia Vicetti Miguel ◽  
Asuncion Mejias ◽  
Amy Leber ◽  
Pablo J. Sanchez

2013 ◽  
Vol 12 ◽  
pp. S1
Author(s):  
S.M.P.J. Prevaes ◽  
K.M. de Winter-de Groot ◽  
G.A. Tramper-Stranders ◽  
H.A.W.M. Tiddens ◽  
M. van Westreenen ◽  
...  

2014 ◽  
Vol 13 ◽  
pp. S67
Author(s):  
C.W. Holmes ◽  
D.W. Rivett ◽  
D.E. Modha ◽  
K.D. Bruce ◽  
E.A. Gaillard

mSystems ◽  
2021 ◽  
Vol 6 (4) ◽  
Author(s):  
Stephen C. Watts ◽  
Louise M. Judd ◽  
Rosemary Carzino ◽  
Sarath Ranganathan ◽  
Kathryn E. Holt

Cystic fibrosis (CF) lung disease begins during infancy, and acute respiratory infections increase the risk of early disease development and progression. Microbes involved in advanced stages of CF are well characterized, but less is known about early respiratory colonizers.


mSphere ◽  
2021 ◽  
Author(s):  
Laura J. Dunphy ◽  
Glynis L. Kolling ◽  
Matthew L. Jenior ◽  
Joanne Carroll ◽  
April E. Attai ◽  
...  

P. aeruginosa is a leading cause of nosocomial infection and infection in patients with cystic fibrosis. While P. aeruginosa infection and treatment can be complicated by a variety of antimicrobial resistance and virulence mechanisms, pathogen virulence is rarely recorded in a clinical setting.


Sign in / Sign up

Export Citation Format

Share Document